Have a feature idea you'd love to see implemented?
Let us know!
VRCA Verrica Pharmaceuticals Inc
Price (delayed)
$0.6557
Market cap
$29.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.84
Enterprise value
$54.05M
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and
Highlights
The revenue has surged by 187% year-on-year but it has declined by 34% since the previous quarter
Verrica Pharmaceuticals's gross profit has soared by 156% YoY but it has decreased by 42% from the previous quarter
The equity has dropped by 180% year-on-year and by 156% since the previous quarter
The quick ratio has plunged by 86% YoY and by 48% from the previous quarter
Key stats
What are the main financial stats of VRCA
Market
Valuations
Earnings
Shares outstanding
45.6M
Market cap
$29.9M
Enterprise value
$54.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.87
Revenue
$9.21M
Gross profit
$6.82M
Net income
-$84.99M
EBIT
-$75.62M
EBITDA
-$74.39M
Free cash flow
-$59.62M
Per share
Balance sheet
Liquidity
EPS
-$1.84
EPS diluted
-$1.84
Free cash flow per share
-$1.27
Book value per share
-$0.8
Revenue per share
$0.2
TBVPS
$0.7
Total assets
$32.93M
Total liabilities
$66.98M
Debt
$47.11M
Equity
-$34.05M
Working capital
$7.16M
Debt to equity
-1.38
Current ratio
1.34
Quick ratio
1.1
Net debt/EBITDA
-0.32
Margins
Efficiency
Dividend
EBITDA margin
-807.7%
Gross margin
74.1%
Net margin
-922.8%
Operating margin
-843.1%
Return on assets
-146%
Return on equity
N/A
Return on invested capital
-180.7%
Return on capital employed
-635.4%
Return on sales
-821.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRCA stock price
How has the Verrica Pharmaceuticals stock price performed over time
Intraday
3.26%
1 week
-12.57%
1 month
-13.83%
1 year
-88.54%
YTD
-6.33%
QTD
-6.33%
Financial performance
How have Verrica Pharmaceuticals's revenue and profit performed over time
Revenue
$9.21M
Gross profit
$6.82M
Operating income
-$77.65M
Net income
-$84.99M
Gross margin
74.1%
Net margin
-922.8%
The revenue has surged by 187% year-on-year but it has declined by 34% since the previous quarter
Verrica Pharmaceuticals's gross profit has soared by 156% YoY but it has decreased by 42% from the previous quarter
The net income has plunged by 76% YoY but it has grown by 2.2% from the previous quarter
VRCA's operating income has dropped by 59% year-on-year but it is up by 4% since the previous quarter
Growth
What is Verrica Pharmaceuticals's growth rate over time
Valuation
What is Verrica Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.87
The EPS has dropped by 72% year-on-year but it is up by 2.6% since the previous quarter
The equity has dropped by 180% year-on-year and by 156% since the previous quarter
The revenue has surged by 187% year-on-year but it has declined by 34% since the previous quarter
The stock's price to sales (P/S) is 90% less than its last 4 quarters average of 31.8
Efficiency
How efficient is Verrica Pharmaceuticals business performance
The return on assets has dropped by 106% year-on-year and by 25% since the previous quarter
The ROS is down by 46% since the previous quarter but it is up by 44% year-on-year
The return on invested capital has increased by 38% year-on-year
Dividends
What is VRCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRCA.
Financial health
How did Verrica Pharmaceuticals financials performed over time
Verrica Pharmaceuticals's total assets is 51% lower than its total liabilities
The quick ratio has plunged by 86% YoY and by 48% from the previous quarter
Verrica Pharmaceuticals's current ratio has shrunk by 83% YoY and by 43% QoQ
The equity has dropped by 180% year-on-year and by 156% since the previous quarter
Verrica Pharmaceuticals's debt to equity has soared by 60% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.